NRXS records strong revenue growth, expanded insurance coverage and new FDA clearances in fourth-quarter 2024.

Q4 2024 Earnings Call Transcript March 20, 2025 Operator: Good day, and thank you for standing by. Welcome to the NeurAxis’ Fourth Quarter 2024 Financial Results Conference Call. At this time, all ...

CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...

Good day, and thank you for standing by. Welcome to the NeurAxis' Fourth Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the ...

Shares of NeurAxis, Inc. NRXS have gained 0.9% since the company reported earnings for the quarter ended Dec. 31, 2024. This compares favorably to the S&P 500 Index, which declined 0.1% over the ...

NeurAxis reports 43% revenue growth in Q4 2024, significant advancements in insurance coverage, and FDA approvals for its technologies. NeurAxis, Inc. reported its fourth quarter and fiscal year ...

Neuraxis Inc. (NRXS) reported a strong fourth quarter for 2024, with revenue increasing significantly. The company’s revenue for the quarter rose by 43% year-over-year to $761,000, while the ...